Hypoparathyroidism (Hormonal Disorders) - Drugs in Development, 2021

September 2021 | 66 pages | ID: H5CD3FFEDCB1EN
Global Markets Direct

Abstracts

Hypoparathyroidism (Hormonal Disorders) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Drugs In Development, 2021, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).
• The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hypoparathyroidism - Overview
Hypoparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hypoparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoparathyroidism - Companies Involved in Therapeutics Development
Aerami Therapeutics Inc
Aeterna Zentaris Inc
Amolyt Pharma
Ascendis Pharma AS
BridgeBio Pharma Inc
Chugai Pharmaceutical Co Ltd
Eli Lilly and Co
Entera Bio Ltd
Extend Biosciences Inc
GC Pharma
ProLynx LLC
Hypoparathyroidism - Drug Profiles
ACP-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aerami-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AEZS-150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZP-3601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLTX-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
encaleret - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-608 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-6272K - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCO-371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-134 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem cell Therapy for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teriparatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypoparathyroidism - Dormant Projects
Hypoparathyroidism - Product Development Milestones
Featured News & Press Releases
Sep 10, 2021: Amolyt Pharma to host key opinion leader webinar and discuss results of phase I clinical trial of AZP-3601 on Friday, October 1st at 10:00am ET
Jul 06, 2021: Ascendis Pharma announces target enrollment achieved in the Phase 3 PaTHway trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism (HP) and provides a comprehensive global clinical program update
Jun 03, 2021: The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
Jun 01, 2021: BridgeBio Pharma receives FDA Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia type 1
May 18, 2021: Amolyt Pharma present new phase 1 data on AZP-3601 its parathyroid hormone analog for hypoparathyroidism, at upcoming scientific conferences
May 12, 2021: Ascendis Pharma announces expansion of global clinical reach for TransCon PTH with filing of the clinical trial notification for phase 3 clinical trial in adults with hypoparathyroidism in Japan
May 10, 2021: Ascendis Pharma announces preliminary 58-week results from open-label extension of phase 2 PaTH forward trial of TransCon PTH in adult hypoparathyroidism demonstrated durable benefit and a well-tolerated safety profile
May 06, 2021: Aeterna Zentaris announces the selection of a development candidate in the DC-PTH program for the potential treatment of primary hypoparathyroidism
May 06, 2021: Ascendis Pharma announces presentations for TransCon PTH at upcoming medical conferences
Mar 23, 2021: Ascendis Pharma presents 6-month open-label extension data from phase 2 path forward trial of TransCon PTH in adult Hypoparathyroidism at ENDO 2021
Mar 22, 2021: Amolyt Pharma presents first clinical data for AZP-3601, its parathyroid hormone analog for hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021)
Mar 20, 2021: BridgeBio Pharma announces proof-of-concept data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting
Mar 16, 2021: Amolyt pharma to present preliminary phase 1 data on AZP-3601 at ENDO 2021
Feb 25, 2021: Entera Bio announces publication of phase 2 hypoparathyroidism study in the Journal of Bone and Mineral Research
Jan 06, 2021: Amolyt Pharma receives Orphan Drug Designation for AZP-3601 for the potential treatment of hypoparathyroidism
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hypoparathyroidism, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Hypoparathyroidism - Pipeline by Aerami Therapeutics Inc, 2021
Hypoparathyroidism - Pipeline by Aeterna Zentaris Inc, 2021
Hypoparathyroidism - Pipeline by Amolyt Pharma, 2021
Hypoparathyroidism - Pipeline by Ascendis Pharma AS, 2021
Hypoparathyroidism - Pipeline by BridgeBio Pharma Inc, 2021
Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, 2021
Hypoparathyroidism - Pipeline by Eli Lilly and Co, 2021
Hypoparathyroidism - Pipeline by Entera Bio Ltd, 2021
Hypoparathyroidism - Pipeline by Extend Biosciences Inc, 2021
Hypoparathyroidism - Pipeline by GC Pharma, 2021
Hypoparathyroidism - Pipeline by ProLynx LLC, 2021
Hypoparathyroidism - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hypoparathyroidism, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021